Omnicell reported second-quarter 2026 results with total revenue of $312.2 million and GAAP net income of $24.3 million. The company posted non-GAAP net income per diluted share of $0.94 and non-GAAP EBITDA of $67.2 million for the quarter. Omnicell updated full-year 2026 guidance, raising non-GAAP EBITDA and non-GAAP EPS ranges while narrowing revenue guidance.

Financial Highlights

  • Total revenues: $312.2 million for Q2 2026 (up $22 million, or 7%, year-over-year).
  • Gross profit: $152.9 million and GAAP gross margin 49.0% for Q2 2026.
  • Income from operations: $32.4 million for Q2 2026.
  • GAAP net income: $24.3 million, or $0.52 per diluted share, for Q2 2026.
  • Non-GAAP net income: $43.5 million, non-GAAP diluted EPS: $0.94; Non-GAAP EBITDA: $67.2 million for Q2 2026.

Business Highlights

  • Demand strength across Omnicell’s connected devices portfolio supported quarter-over-quarter revenue growth in North America and international markets.
  • Growth in SaaS and Expert Services and technical services revenue contributed to overall revenue expansion.
  • Operational cash generation improved: cash and cash equivalents of $292.2 million and operating cash flow of $68.3 million in Q2; $350 million available on the revolving credit facility with no outstanding balance.
  • Leadership and organizational changes to support growth: promotion of Nnamdi Njoku to President & COO and creation of senior pharmacy/clinical and specialty pharmacy leadership roles to advance product and specialty pharmacy initiatives.
  • Company received $15 million in IEEPA tariff refunds in the quarter, which primarily reduced cost of product revenues and favorably impacted reported profitability and cash flows.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.